APM
EVLO

Avidity Partners Management’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Avidity Partners Management’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-40,000
Closed -$8.56M – 140
2021
Q1 		$8.56M Buy
+40,000
New +$11.1M 0.24% 76

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Avidity Partners Management's EVLO Position: Q2 2021 in Review

Avidity Partners Management sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q2 2021, closing a stake of 40,000 shares — an estimated $8.56M sold.

Avidity Partners Management first reported a position in EVLO in Q1 2021 and held it in 1 quarter. The position peaked at $8.56M in Q1 2021. 66 funds tracked by Wall St. Rank hold EVLO as of Q2 2021.

  • Avidity Partners Management reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Avidity Partners Management sold 40,000 Evelo Biosciences, Inc. Common Stock shares in Q2 2021, an estimated $8.56M.
  • Avidity Partners Management first reported a position in Evelo Biosciences, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Avidity Partners Management's Evelo Biosciences, Inc. Common Stock position peaked at $8.56M in Q1 2021.
  • 66 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q2 2021.

Based on Avidity Partners Management's 13F filing for Q2 2021, filed 16 Aug 2021.